BACKGROUND: To evaluate cause-specific mortality following radical prostatectomy (RP) in a population cohort of US men adjusting for competing risks.
Introduction
Cardiovascular diseases and malignancies are the two most common causes of death in men 440 years in the United States. 1 Although prostate cancer is responsible for 25% of all newly diagnosed male cancers in the United States, it contributes 9% to male cancer-related deaths.
Approximately 192 000 new prostate cancer cases were diagnosed in the United States in 2009. 1 Radical prostatectomy (RP) is a commonly used treatment for the B85% diagnosed with clinically localized cancer. The long-term prostate cancer-specific mortality (PCSM) after RP is very low, B2% at 10 years and 7% at 15 years. 2 Understanding the cause-specific mortality following RP is important for individual patient counseling, optimizing overall health, and promoting lifestyle modifications.
To date, reports on mortality following RP have mostly focused on PCSM, either originating from institutional experiences, small population-based series, or from the pre-PSA era. 3 A few large population-based studies have described cause-specific mortality in men with prostate cancer but did not account for treatment modality and were limited to elderly patients. 3, 4 We analyzed a large population-based cohort of men treated with RP for localized prostate cancer in the PSA era to determine the overall prostate cancer-specific and other cause-specific mortality. (Appendix A).
Materials and methods

Study cohort
Statistical analysis
Cumulative incidence of cause-specific mortality was calculated using the competing risks approach, 8, 9 a method shown to be more accurate compared with Kaplan-Meier method in the presence of multiple types of failure. Confidence intervals were calculated using the Marubini and Valsecchi formula. 10 Analyses were performed using the stcompet function in Stata 11 (StataCorp, College Station, TX, USA).
Results
Baseline parameters of the study population are summarized in Table 1 . Median (range) age was 63 (32-75) years and 58% were o65 years. Pathologic Gleason score p7 was present in 80% with local, regional, and unstaged cancers in 32, 28, and 40%, respectively. Overall, 19 142 (16%) of patients had died at last follow-up. Of these, 2965 (15%) died from prostate cancer, 5283 (28%) from other cancers, 5721 (30%) from cardiovascular diseases, and 5173 (27%) from other causes. Among other-cancer mortality, the most common were respiratory (32%), gastrointestinal (28%), hematological (13%), and genitourinary (8%).
The 5, 10, and 15-year cumulative incidence of death due to non-prostate cancer causes following prostatectomy was 4.8%, 14.4% and 30.6%, respectively. The 5, 10, and 15-year PCSM was 0.8%, 2.9% and 5%, respectively ( Figure 1 ; Table 2 ). The rate of death from non-prostate cancer cause was 4.9-6.1 times higher than rate of death from prostate cancer at each 5-year interval.
Among men of age X65 years, the 5, 10, and 15-year cumulative incidence of death due to non-prostate cancer causes following prostatectomy was 7.2, 20.6 and 40.8% ( Table 2 ). The 5, 10, and 15-year PCSM was 1.0%, 3.6% and 6.0%, respectively ( Figure 1 ). The rate of death from non-prostate cancer causes was 5.7-7.2 times higher than rate of death from prostate cancer at each 5-year interval compared with men o65 years ( Figure 2a) .
The 15-year PCSM in men with pathologic Gleason p7 was 3.7% and in men with Gleason X8 was 12.7%. The 15-year PCSM in men with localized cancers was 3.6% and in men with regional cancers was 8.0% (Table 2) .
Cardiovascular diseases, other cancers, and other causes showed nearly equal contribution to cumulative incidence of mortality and were each approximately twice higher than mortality due to prostate cancer (Figure 2b ). At 15 years following surgery, 11% of men had died from cardiovascular diseases, 9.1% from other malignancies, and 10.5% from other causes ( Table 3) .
Discussion
In a large population-based evaluation of US men undergoing RP in the PSA era, we observed 5% dying from prostate cancer within 15 years following surgery, and approximately six times more dying due to other causes. Our findings confirm heart disease and other cancers remain the two leading causes of cancer death among men being treated with RP, similar to the entire population of men without prostate cancer over age 40. 1 Even among men o65 years and those with high-grade or high-stage tumors, the risk of non-prostate cancer death remained at least fivefold higher. These findings emphasize the importance of urologists and other health care professionals to initiate preventive health measures, lifestyle modifications, and screening of other cancers.
Many men treated for localized prostate cancer overestimate the risk posed by the cancer and simultaneously Estimates of cause-specific mortality S Shikanov et al underestimate the risk posed by more chronic conditions such as obesity, hypertension, and cardiovascular disease. In a study evaluating lifestyle modifications in cancer survivors, Blanchard et al. 11 found that among 2226 prostate cancer survivors only 5% adhered to appropriate exercise, dietary, and non-smoking behavior. Our findings regarding PCSM are similar to those found in other country, statewide, and institutional experiences. Recently, the Swedish national registry reported a 1.7% risk of PCSM at 10 years following RP. 12 Similarly, in a cohort derived from the Connecticut Tumor Registry, Albertsen et al. 13 showed a 3% PCSM rate at 10 years following RP. In a large multi-institutional series of 11 000 patients, the 15-year PCSM following RP was 7% and non-cancer mortality was 33%. 2 Uniquely, our data lend insight into the relative contributions of non-prostate cancer causes of mortality and therefore provides general measures that may improve the overall health and life expectancy of men Other malignancies Total 1.8 (1.7-1.9) 5.0 (4.9-5.2) 9.1 (8.9-9.4) o65 years 1.1 (1.0-1.2) 3.4 (3.2-3.6) 6.7 (6.3-7.1) X65 years 2.6 (2.5-2.8) 6.8 (6.6-7.1) 11.5 (11.0-11.9)
Other causes Estimates of cause-specific mortality S Shikanov et al treated for localized prostate cancer. The non-PCSM in our series was B30% at 15 years following surgery with nearly equal risks from cardiovascular disease, other cancers, and other causes. In a study of 584 men diagnosed with prostate cancer between 1980 and 1984 by Satariano et al. 3 approximately one-half of nonprostate cancer deaths were due to cardiovascular causes and one-fourth were due to other cancers. Of note, that cohort was comprised of an elderly population (median age 470 years), one-third were treated with hormonal therapy as primary treatment and competing risks approach was not used, which may lead to overestimation of incidence rates. 9, 14 In a recent analysis of SEER database Abdollah et al. 15 have shown similar estimates of cause-specific mortality after RP without evaluation of underlying causes of non-cancer-related deaths.
Relatively few studies have assessed the impact of age on other-cause mortality in men undergoing RP. Among men treated at the age of X65 years, we observed an absolute increased 15-year PCSM risk of 1.4% (6.0 vs 4.6%) compared with men o65 years, and an absolute increased 15-year non-cancer-specific risk of 21.9% (40.8 vs 18.9%). Although a randomized study has shown a lower risk of PCSM for men treated with RP compared with watchful waiting, 16 this difference was limited to men under age 65. Of note, in our cohort men of X65 years had a 6% higher incidence of extraprostatic disease and 5% higher incidence of Gleason 8 or higher tumors. This is likely due to differences in age-related presentation, tumor biology, or likelihood of undergoing prostatectomy. Our findings, along with those from the randomized study, are important to consider when presenting management options to men over age 65, particularly those with significant or multiple competing risks.
We found higher stage and grade to be associated with a higher risk of PCSM and non-prostate cancer mortality. Although we were not able to extract data on secondary therapies, it is likely these men more commonly received androgen deprivation therapy that has been associated with an increased risk of cardiovascular morbidity and sudden cardiac death. 17, 18 The strengths of our study include its size, resulting in robust estimates, and narrow confidence intervals. Additionally, the population-based nature of the study contributes to the external validity of our findings. Lastly, competing risks approach provides more accurate results compared with Kaplan-Meier estimates.
There are also several limitations to consider when interpreting our findings. Defining cause of death using death certificates may be imprecise, especially in an elderly population with multiple comorbidities. However, reasonable accuracy has been shown when comparing death certificates to review of medical records. 19 The median follow-up was 7 years; 5% of patients had follow-up beyond 15 years. However, the large volume of the cohort allowed the detection of statistically significant low-magnitude differences (2-3%) at 15-years following surgery. We also did not control for the presence of baseline comorbidities and risk factors. Furthermore, we did not extract rates, timing, or types of secondary therapy as they are not reported in SEER. The use of SEER-Medicare data may have been able to overcome this limitation at the expense of excluding patients o65 years.
Conclusions
Our study provides population-based estimates of long-term cause-specific mortality after RP. At 15 years following prostatectomy, B5% will die from prostate cancer and 30% from other causes. Cardiovascular diseases, other cancers, and other causes contribute equally to non-prostate cancer mortality. Men of X65 years have double the rate of non-prostate cancer mortality. To improve overall survival of men undergoing RP for prostate cancer, significant effort is needed to prevent, identify, and treat other medical conditions.
